<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.112063</article-id><article-id pub-id-type="publisher-id">ACM-40296</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210200000_72258679.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  非布司他对射血分数保留的心衰患者预后的影响
  Effect of Febuxostat on Prognosis of Heart Failure Patients with Ejection Fraction Retention
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>沛羲</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>瞳</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>利方</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>耿</surname><given-names>凡琪</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>雪娟</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属医院全科医学科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>青岛大学，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>02</month><year>2021</year></pub-date><volume>11</volume><issue>02</issue><fpage>444</fpage><lpage>450</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：通过病例对照研究评估非布司他对射血分数保留心力衰竭患者的影响。方法：采用病例对照研究方法，连续性收集2014至2017于青岛大学附属医院住院治疗的伴有高尿酸血症的射血分数保留心力衰竭患者，跟踪随访1年的276例，将其分为常规治疗组、非布司他组。常规治疗组采用标准抗心衰治疗；非布司他组在标准抗心衰治疗基础上应用非布司他降尿酸治疗；分别收集随访治疗1年前后血压、血尿酸、心房尿钠肽(BNPB-type natriuretic peptide)水平，利用超声心动图测定的左室射血分数(LVEFleft ventricular ejection fractions)、左房内径(LADleft atrial dimension)、计算左心室重量指数(LVMIleft ventricular mass index)、E/e′比值，记录非布司他组与常规治疗组患者1年心血管事件的发生情况。结果：随访观察12个月后，非布司他组和常规治疗组患者的E/e′、LVMI均呈下降趋势，非布司他组下降更明显，差异有统计学意义(均为P &lt; 0.05)。结论：长期应用非布司他在有效降尿酸的同时可改善射血分数保留心力衰竭患者的预后。
    Objective: To evaluate the effect of febuxostat on ejection fraction retention in patients with heart failure through a case-control study. Methods: A case-control study was conducted and collected continuously from 2014 to 2017 at Qingdao University. Patients with ejection fraction reserved heart failure with hyperuricemia who were hospitalized in affiliated hospitals were followed up 1. A total of 276 patients were divided into conventional treatment group and non-buxostat group. Standard anti-heart failure therapy was used in the conventional treatment group. On the basis of standard anti-heart failure treatment, febuxostat was used to reduce uric acid. Were collected before and after treatment 1 year follow-up blood pressure, blood uric acid, atrial urinary sodium peptide (BNPB-type natriuretic peptide) levels, measured by echocardiography of left ventricular ejection fraction (LVEFleft ventricular ejection fractions), left atrial diameter (LADleft atrial dimension), calculate the left ventricular mass index (LVMIleft ventricular mass index), E/e′ ratio, record not cloth company he group and routine treatment group patients 1 year the happening of cardiovascular events. Results: After 12 months of follow-up observation, E/e′ and LVMI decreased in both the febuxostat group and the conventional treatment group, while the decline was more obvious in the febuxostat group, with statistically significant differences (all P &lt; 0.05). Conclusion: Long-term application of febuxostat can effectively lower uric acid and improve the prognosis of patients with ejection fraction retention heart failure. 
  
 
</p></abstract><kwd-group><kwd>非布司他，射血分数保留的心力衰竭，高尿酸血症，病例对照研究, Febuxostat</kwd><kwd> Heart Failure with Ejection Fraction Retention</kwd><kwd> Hyperuricemia</kwd><kwd> Case Control Study</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：通过病例对照研究评估非布司他对射血分数保留心力衰竭患者的影响。方法：采用病例对照研究方法，连续性收集2014至2017于青岛大学附属医院住院治疗的伴有高尿酸血症的射血分数保留心力衰竭患者，跟踪随访1年的276例，将其分为常规治疗组、非布司他组。常规治疗组采用标准抗心衰治疗；非布司他组在标准抗心衰治疗基础上应用非布司他降尿酸治疗；分别收集随访治疗1年前后血压、血尿酸、心房尿钠肽(BNPB-type natriuretic peptide)水平，利用超声心动图测定的左室射血分数(LVEFleft ventricular ejection fractions)、左房内径(LADleft atrial dimension)、计算左心室重量指数(LVMIleft ventricular mass index)、E/e′比值，记录非布司他组与常规治疗组患者1年心血管事件的发生情况。结果：随访观察12个月后，非布司他组和常规治疗组患者的E/e′、LVMI均呈下降趋势，非布司他组下降更明显，差异有统计学意义(均为P &lt; 0.05)。结论：长期应用非布司他在有效降尿酸的同时可改善射血分数保留心力衰竭患者的预后。</p></sec><sec id="s2"><title>关键词</title><p>非布司他，射血分数保留的心力衰竭，高尿酸血症，病例对照研究</p></sec><sec id="s3"><title>Effect of Febuxostat on Prognosis of Heart Failure Patients with Ejection Fraction Retention</title><p>Peixi Wu<sup>1*</sup>, Tong Chen<sup>2</sup>, Lifang Zhang<sup>2</sup>, Fanqi Geng<sup>2</sup>, Xuejuan Zhang<sup>2#</sup></p><p><sup>1</sup>Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of General Medicine, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/2-1571886x5_hanspub.png" /></p><p>Received: Jan. 3<sup>rd</sup>, 2021; accepted: Jan. 25<sup>th</sup>, 2021; published: Feb. 7<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/2-1571886x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To evaluate the effect of febuxostat on ejection fraction retention in patients with heart failure through a case-control study. Methods: A case-control study was conducted and collected continuously from 2014 to 2017 at Qingdao University. Patients with ejection fraction reserved heart failure with hyperuricemia who were hospitalized in affiliated hospitals were followed up 1. A total of 276 patients were divided into conventional treatment group and non-buxostat group. Standard anti-heart failure therapy was used in the conventional treatment group. On the basis of standard anti-heart failure treatment, febuxostat was used to reduce uric acid. Were collected before and after treatment 1 year follow-up blood pressure, blood uric acid, atrial urinary sodium peptide (BNPB-type natriuretic peptide) levels, measured by echocardiography of left ventricular ejection fraction (LVEFleft ventricular ejection fractions), left atrial diameter (LADleft atrial dimension), calculate the left ventricular mass index (LVMIleft ventricular mass index), E/e′ ratio, record not cloth company he group and routine treatment group patients 1 year the happening of cardiovascular events. Results: After 12 months of follow-up observation, E/e′ and LVMI decreased in both the febuxostat group and the conventional treatment group, while the decline was more obvious in the febuxostat group, with statistically significant differences (all P &lt; 0.05). Conclusion: Long-term application of febuxostat can effectively lower uric acid and improve the prognosis of patients with ejection fraction retention heart failure.</p><p>Keywords:Febuxostat, Heart Failure with Ejection Fraction Retention, Hyperuricemia, Case Control Study</p><disp-formula id="hanspub.40296-formula17"><graphic xlink:href="//html.hanspub.org/file/2-1571886x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-1571886x8_hanspub.png" /> <img src="//html.hanspub.org/file/2-1571886x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>射血分数保留心力衰竭(HFpEF)以心肌舒张功能异常、顺应性减退、僵硬度增高为主要特征，可占到全部心力衰竭患者的50%，其发病率、死亡率和医疗成本与射血分数降低心力衰竭(HFrEF)相当 [<xref ref-type="bibr" rid="hanspub.40296-ref1">1</xref>]。近年来，HFrEF的预后已明显改善，但关于HFpEF预后相关的临床研究相对较少，与其涵盖人群的异质性和病理、生理机制的复杂性、多样性有关 [<xref ref-type="bibr" rid="hanspub.40296-ref2">2</xref>]。</p><p>目前通常认为高尿酸血症与各种临床疾病，例如代谢综合征，高血压，左心室肥大(LVH)，糖尿病，冠状动脉疾病(CAD)和心力衰竭(HF)密切相关，尤其是尿酸已被证明可影响心衰患者的预后和心血管死亡风险有关 [<xref ref-type="bibr" rid="hanspub.40296-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.40296-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.40296-ref5">5</xref>]。相关研究表明尿酸升高同时与LVH和左心室(LV)舒张功能障碍以及高血压患者新发HFpEF的发生率有关 [<xref ref-type="bibr" rid="hanspub.40296-ref6">6</xref>]。但目前为止在中国人群中并没有太多临床研究来证实降尿酸治疗对射血分数保留心力衰竭患者的进展和预后的影响。这项研究的主要目的是确定长期使用黄嘌呤氧化酶(XO)抑制剂(非布司他)是否有益于改善HFpEF患者的LVH，LV舒张功能和HFpEF症状再发。</p></sec><sec id="s6"><title>2. 对象和方法</title><sec id="s6_1"><title>2.1. 对象</title><p>入选2014年至2017年在我院心内科/全科医学科住院的合并高尿酸血症的射血分数保留的心力衰竭患者276例，高尿酸血症诊断标准：空腹血尿酸浓度男性 ≥ 420 μmol/L，女性 ≥ 360 μmol/L (绝经后女性诊断标准与男性相同)。HFpEF患者入选标准 [<xref ref-type="bibr" rid="hanspub.40296-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.40296-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.40296-ref9">9</xref>]：(1) 存在心力衰竭症状和或体征；(2) 左心室射血分数(LV EF) ≥ 50%；(3) B型钠尿肽(BNP)水平 &gt; 35 ng/L或N末端B型利钠肽原(NT-proBNP) &gt; 125 ng/L；(4) 心脏功能性和或结构性改变的超声心动图客观证据。排除标准：非布司他过敏或不耐受、HFrEF、近期发生急性冠脉综合征伴或不伴血运重建(&lt;6周)、严重瓣膜病、心肌病、心包疾病、未控制的高血压或严重心律失常、严重肺部疾病、卒中、肿瘤、自身免疫性疾病等。其他排除标准有急性或慢性感染、贫血、肝肾功能明显异常。</p></sec><sec id="s6_2"><title>2.2. 分组</title><p>根据患者入院后是否使用非布司他分为两组。其中应用非布司他治疗的121例患者作为非布司他组，未接受降尿酸药物治疗的155例患者作为常规治疗组。非布司他组患者与常规治疗组患者均接受基础抗心力衰竭治疗。包括硝酸酯类、利尿剂、醛固酮受体抑制剂、血管紧张素受体转换酶抑制剂、血管紧张素II受体拮抗剂、钙离子通道阻断剂、抗血小板、他汀类等药物治疗；而非布司他组患者加用起始剂量20 mg Qd的非布司他降尿酸治疗。</p></sec><sec id="s6_3"><title>2.3. 方法</title><p>我们采用了病例对照研究和随访，以查阅病历的方式，收集患者资料，其中包括了患者的一般情况、既往史、药物使用情况、体格检查和实验室检查等临床资料。实验室检查均为入院后第二天清晨空腹取外周静脉血所检测的结果；心脏超声结果均为入院后首次测定超声心动图的结果。2018年1月对患者统一随访，随访12个月。采用电话通知患者回院随访的方式，并通过医院his系统采集1年内复诊病史，对心血管事件的发生进行确认。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>应用SPSS23.0软件进行统计学分析。所有计量资料以均数 &#177; 标准差(x &#177; s)表示，采用t检验比较组间统计学差异。用Kaplan-Meier统计分析了12个月随访期再入院情况。利用Log-Rank检验计算因素间差异。将单因素分析有意义的变量引入COX比例风险模型进行多因素分析，得出影响心衰患者心血管事件的独立因素。以P &lt; 0.05表示差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><p>出院后随访1年的两组情况：常规治疗组患者长期采用基础抗心力衰竭治疗，非布司他组患者中有1例因“非布司他过敏”而终止研究，其余患者均长期采用非布司他20~40 mg Qd的剂量降尿酸治疗，未出现肝肾功能、白细胞异常及明显药物相关的过敏与胃肠道反应等不良反应。</p><sec id="s7_1"><title>3.1. 基本资料比较</title><p>非布司他组与常规治疗组在年龄、性别、吸烟史、高血压病史、冠心病/房颤病史、糖尿病病史、用药情况、尿酸/肌酐清除率、体重指数方面比较未见统计差异。见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Basic data of the two groups were compare</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >非布司他组 (N = 121)</th><th align="center" valign="middle" >常规治疗组组 (N = 155)</th><th align="center" valign="middle" >p值</th></tr></thead><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >67.8 &#177; 6.5</td><td align="center" valign="middle" >67.6 &#177; 8.3</td><td align="center" valign="middle" >0.814</td></tr><tr><td align="center" valign="middle" >男性(%)</td><td align="center" valign="middle" >81 (66.9)</td><td align="center" valign="middle" >103 (66.5)</td><td align="center" valign="middle" >0.854</td></tr><tr><td align="center" valign="middle" >体重指数(kg/m<sup>2</sup>)</td><td align="center" valign="middle" >25.2 &#177; 2.3</td><td align="center" valign="middle" >24.8 &#177; 2.6</td><td align="center" valign="middle" >0.170</td></tr><tr><td align="center" valign="middle" >吸烟(%)</td><td align="center" valign="middle" >26 (21.5)</td><td align="center" valign="middle" >34 (21.9)</td><td align="center" valign="middle" >0.734</td></tr><tr><td align="center" valign="middle" >糖尿病(%)</td><td align="center" valign="middle" >22 (18.1)</td><td align="center" valign="middle" >20 (12.9)</td><td align="center" valign="middle" >0.142</td></tr><tr><td align="center" valign="middle" >高血压病程(年)</td><td align="center" valign="middle" >10.6 &#177; 3.3</td><td align="center" valign="middle" >10.3 &#177; 3.2</td><td align="center" valign="middle" >0.587</td></tr><tr><td align="center" valign="middle" >心房颤动(%)</td><td align="center" valign="middle" >5 (4.1)</td><td align="center" valign="middle" >13 (8.4)</td><td align="center" valign="middle" >0.112</td></tr><tr><td align="center" valign="middle" >钙阻滞剂(%)</td><td align="center" valign="middle" >83 (68.8)</td><td align="center" valign="middle" >105 (67.7)</td><td align="center" valign="middle" >0.874</td></tr><tr><td align="center" valign="middle" >硝酸酯类</td><td align="center" valign="middle" >57 (47.1)</td><td align="center" valign="middle" >62 (40.0)</td><td align="center" valign="middle" >0.417</td></tr><tr><td align="center" valign="middle" >利尿剂</td><td align="center" valign="middle" >17 (14.0)</td><td align="center" valign="middle" >22 (14.2)</td><td align="center" valign="middle" >0.862</td></tr><tr><td align="center" valign="middle" >醛固酮拮抗剂</td><td align="center" valign="middle" >9 (7.4)</td><td align="center" valign="middle" >12 (7.7)</td><td align="center" valign="middle" >0.899</td></tr><tr><td align="center" valign="middle" >ACEI/ARB</td><td align="center" valign="middle" >80 (66.1)</td><td align="center" valign="middle" >102 (65.8)</td><td align="center" valign="middle" >0.902</td></tr><tr><td align="center" valign="middle" >尿酸(umol/L)</td><td align="center" valign="middle" >494.0 &#177; 73.8</td><td align="center" valign="middle" >494.1 &#177; 70.3</td><td align="center" valign="middle" >0.987</td></tr><tr><td align="center" valign="middle" >eGFR</td><td align="center" valign="middle" >78.4 &#177; 9.2</td><td align="center" valign="middle" >77.3 &#177; 10.0</td><td align="center" valign="middle" >0.342</td></tr><tr><td align="center" valign="middle" >BNP (pg/ml)</td><td align="center" valign="middle" >67.5 &#177; 19.6</td><td align="center" valign="middle" >66.9 &#177; 22.4</td><td align="center" valign="middle" >0.808</td></tr><tr><td align="center" valign="middle" >收缩压(mmHg)</td><td align="center" valign="middle" >150.2 &#177; 11.3</td><td align="center" valign="middle" >149.2 &#177; 12.0</td><td align="center" valign="middle" >0.382</td></tr><tr><td align="center" valign="middle" >舒张压(mmHg)</td><td align="center" valign="middle" >90.0 &#177; 8.8</td><td align="center" valign="middle" >89.6 &#177; 9.2</td><td align="center" valign="middle" >0.674</td></tr><tr><td align="center" valign="middle" >左室重量指数(g/m<sup>2</sup>)</td><td align="center" valign="middle" >144.9 &#177; 14.4</td><td align="center" valign="middle" >143.2 &#177; 14.3</td><td align="center" valign="middle" >0.247</td></tr><tr><td align="center" valign="middle" >左室射血分数(%)</td><td align="center" valign="middle" >62.1 &#177; 5.0</td><td align="center" valign="middle" >63.1 &#177; 5.1</td><td align="center" valign="middle" >0.146</td></tr><tr><td align="center" valign="middle" >LAD (毫米)</td><td align="center" valign="middle" >38.5 &#177; 2.1</td><td align="center" valign="middle" >38.7 &#177; 2.3</td><td align="center" valign="middle" >0.417</td></tr><tr><td align="center" valign="middle" >E/e′</td><td align="center" valign="middle" >11.0 &#177; 1.7</td><td align="center" valign="middle" >10.9 &#177; 1.4</td><td align="center" valign="middle" >0.574</td></tr></tbody></table></table-wrap><p>表1. 两组患者基本资料比较</p></sec><sec id="s7_2"><title>3.2. 治疗后超声心动图和临床基线的变化</title><p>与治疗前相比，非布司他组血尿酸水平下降明显，与常规治疗组比较有显著差异(P &lt; 0.01)。两组的血压水平较治疗前有下降改变，两组间无明显差异。非布司他组(−0.3 &#177; 0.4, P &lt; 0.01)与常规治疗组E/e′都有明显下降(−0.2 &#177; 0.3, P &lt; 0.05)。在非布司他组E/e'的变化更为明显(P = 0.020)，两组的BNP水平也较治疗前均有下降，但两组间无明显差异(−6.6 &#177; 26.0 pg/ml与−1.6 &#177; 34.0 pg/ml, P = 0.202)。两组LVMI较治疗前也有明显下降(−3.2 &#177; 3.9与−1.9 &#177; 2.3)，在非布司他组这种下降仍更显著，有统计学差异(P &lt; 0.01)。同时我们观察到非布司他组在治疗过程中eGFR较治疗前无明显改变，可能与降尿酸治疗对肾功能的保护有关。见表2。</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Changes of echocardiography and biochemical indexe</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >非布司他组(N = 121)</th><th align="center" valign="middle" >常规治疗组(N = 155)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >收缩压(mmHg)</td><td align="center" valign="middle" >−15.2 &#177; 12.3</td><td align="center" valign="middle" >−14.9 &#177; 13.4</td><td align="center" valign="middle" >0.862</td></tr><tr><td align="center" valign="middle" >舒张压(mmHg)</td><td align="center" valign="middle" >−9.2 &#177; 8.2</td><td align="center" valign="middle" >−9.4 &#177; 7.9</td><td align="center" valign="middle" >0.849</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >尿酸(umol/ L)</th><th align="center" valign="middle" >−177.0 &#177; 70.5</th><th align="center" valign="middle" >−40.5 &#177; 57.3</th><th align="center" valign="middle" >&lt;0.001</th></tr></thead><tr><td align="center" valign="middle" >eGFR</td><td align="center" valign="middle" >1.1 &#177; 7.5</td><td align="center" valign="middle" >−2.8 &#177; 8.7</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >左室重量指数(g/m<sup>2</sup>)</td><td align="center" valign="middle" >−3.2 &#177; 3.9</td><td align="center" valign="middle" >−1.9 &#177; 2.3</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >E/e′</td><td align="center" valign="middle" >−0.3 &#177; 0.4</td><td align="center" valign="middle" >−0.2 &#177; 0.3</td><td align="center" valign="middle" >0.020</td></tr><tr><td align="center" valign="middle" >左室射血分数(%)</td><td align="center" valign="middle" >0.2 &#177; 1.5</td><td align="center" valign="middle" >0.2 &#177; 1.7</td><td align="center" valign="middle" >1.000</td></tr><tr><td align="center" valign="middle" >LAD (毫米)</td><td align="center" valign="middle" >0.1 &#177; 0.6</td><td align="center" valign="middle" >0.1 &#177; 0.5</td><td align="center" valign="middle" >1.000</td></tr><tr><td align="center" valign="middle" >BNP (pg/ml)</td><td align="center" valign="middle" >−6.6 &#177; 26.0</td><td align="center" valign="middle" >−1.6 &#177; 34.0</td><td align="center" valign="middle" >0.202</td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. 超声心动图和生化指标的变化</p></sec><sec id="s7_3"><title>3.3. 随访心血管事件分析</title><p>在1年的随访期内，有23名(14.8%)常规治疗组和8名非布司他组患者(6.6%)因心功能不全再次入院治疗。用Kaplan-Meier统计分析，应用非布司他可有效降低射血分数保留心衰患者再住院率，差异达到统计学意义(P = 0.034)，见图1。</p><p>图1. 应用Kaplan-Meier法绘制射血分数保留的心力衰竭患者再入院的生存曲线</p></sec><sec id="s7_4"><title>3.4. 高尿酸血症合并心力衰竭患者心血管事件的多因素COX回归分析</title><p>Log-Rank检验结果显示：年龄，LVMI，E/e′，ACEI/ARB药物治疗，血尿酸，和非布司他治疗均与患者再入院有关(P &lt; 0.10)，将上述单因素分析中有意义的变量引入多因素COX比例风险模型进行多因素分析，结果显示：ACEI/ARB治疗(HR0.247，95% CI为0.062~0.984，P &lt; 0.05)可降低高尿酸血症合并射血分数保留心衰患者的再入院风险，而年龄，LVMI，E/e′可能是心衰患者再入院的影响因素。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>研究表明射血分数保留的心衰患者黄嘌呤氧化酶的水平和酶活性均有升高 [<xref ref-type="bibr" rid="hanspub.40296-ref10">10</xref>]，这条通路上调将导致血管收缩和心脏功能降低，这二者是慢性心力衰竭的标志 [<xref ref-type="bibr" rid="hanspub.40296-ref11">11</xref>]，这种酶活性增强将导致氧化应激和血尿酸水平升高 [<xref ref-type="bibr" rid="hanspub.40296-ref12">12</xref>]。通过我们的研究可以看出，与治疗前相比，两组的血尿酸水平均有下降，但非布司他组下降更为明显。两组的LMVI较治疗前有下降改变，非布司他组的LMVI下降较常规治疗组相比有显著差异。非布司他组与常规治疗组的E/e′也表现出相同的改变，非布司他组的E/e′下降更多。同时我们发现，非布司他组的eGFR与治疗前相比无明显变化，而常规治疗组的eGFR较治疗前相比有一定程度下降，可能与非布司他对肾功能的保护相关。从随访再入院分析可得出，应用非布司他治疗可显著降低射血分数保留心衰患者的再入院率。高尿酸血症合并射血分数保留心衰患者再入院的多因素COX回归分析表明，ACEI/ARB的应用可降低高尿酸血症合并射血分数保留心衰患者的再入院风险，而年龄、LVMI、E/e′则可能是心衰患者再入院的影响因素。</p><p>在射血分数保留的慢性心衰中，血清尿酸水平增高主要以生成增多为主，肾脏排泄能力一般处于正常水平。黄嘌呤氧化还原酶在嘌呤核苷酸分解代谢过程中起着重要的作用在生成尿酸的同时，产生活性氧(ROS)。在一些病理状态下，如胰岛素抵抗、组织缺氧、细胞坏死、免疫激活以及高代谢状态等，可上调黄嘌呤氧化酶活性，加速嘌呤分解代谢，生成大量尿酸和活性氧簇。在心衰发生发展过程中，黄嘌呤氧化酶的活性可通过血尿酸水平进行反映。目前研究发现，左心室射血分数保留的心衰竭患者血尿酸水平的增高与其心肌组织中黄嘌呤氧化酶活性的增强具有一定的相关性。因此可认为黄嘌呤氧化酶水平增高与左心室射血分数保留的心力衰竭患者心功能的恶化有关，后者并促进了心脏的氧化应激反应，进一步增加了对心肌的损害程度。非布司他是一种非选择性黄嘌呤氧化酶抑制剂，因具有强效的降尿酸作用，在临床上已经广泛用于高尿酸血症及痛风的治疗。它可以通过抑制黄嘌呤氧化酶的活性来减少活性氧簇和尿酸的生成。黄嘌呤氧化酶降解嘌呤形成尿酸，非布司他可以抑制其活性，降低血尿酸分解，从而抑制氧化应激，改善内皮细胞活性，增强心肌收缩力，改善心室重构，从而防止患者心功能进一步恶化。实验证明，在标准抗心衰治疗的基础上加用非布司他可以给射血分数保留的心衰患者心功能带来益处。</p></sec><sec id="s9"><title>声明</title><p>该病例报道已获得病人知情同意。</p></sec><sec id="s10"><title>文章引用</title><p>吴沛羲,陈 瞳,张利方,耿凡琪,张雪娟. 非布司他对射血分数保留的心衰患者预后的影响Effect of Febuxostat on Prognosis of Heart Failure Patients with Ejection Fraction Retention[J]. 临床医学进展, 2021, 11(02): 444-450. https://doi.org/10.12677/ACM.2021.112063</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40296-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Steinberg, B.A., Zhao, X., Heidenreich, P.A., et al. (2012) Trends in Patients Hospitalized with Heart Failure and Preserved Left Ventricular Ejection Fraction Clinical Perspective. Circulation, 126, 65-75.  
&lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.111.080770</mixed-citation></ref><ref id="hanspub.40296-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ferrari, R., Böhm, M., Cleland, J.G.F., et al. (2015) Heart Failure with Preserved Ejection Fraction: Uncertainties and Dilemmas. European Journal of Heart Failure, 17, 665-671. &lt;br&gt;https://doi.org/10.1002/ejhf.304</mixed-citation></ref><ref id="hanspub.40296-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Biscaglia, S., Ceconi, C., Malagù, M., Pavasini, R. and Ferrari, R. (2016) Uric Acid and Coronary Artery Disease: An Elusive Link Deserving Further Attention. International Journal of Cardiology, 213, 28-32.  
&lt;br&gt;https://doi.org/10.1016/j.ijcard.2015.08.086</mixed-citation></ref><ref id="hanspub.40296-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Doehner, W., Jankowska, E.A., Springer, J., Lainscak, M. and Anker, S.D. (2016) Uric Acid and Xanthine Oxidase in Heart Failure—Emerging Data and Therapeutic Implications. International Journal of Cardiology, 213, 15-19.  
&lt;br&gt;https://doi.org/10.1016/j.ijcard.2015.08.089</mixed-citation></ref><ref id="hanspub.40296-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Volterrani, M., Iellamo, F., Sposato, B. and Romeo, F. (2016) Uric Acid Lowering Therapy in Cardiovascular Diseases. International Journal of Cardiology, 213, 20-22. &lt;br&gt;https://doi.org/10.1016/j.ijcard.2015.08.088</mixed-citation></ref><ref id="hanspub.40296-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Gu, J., Fan, Y.Q., Zhang, H.L., Zhang, J.F. and Wang, C.Q. (2018) Serum Uric Acid Is Associated with Incidence of Heart Failure with Preserved Ejection Fraction and Cardiovascular Events in Patients with Arterial Hypertension. The Journal of Clinical Hypertension (Greenwich), 20, 560-567. &lt;br&gt;https://doi.org/10.1111/jch.13210</mixed-citation></ref><ref id="hanspub.40296-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Yancy, C.W., Jessup, M., Bozkurt, B., et al. (2016) 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology, 68, 1476-1488.  
&lt;br&gt;https://doi.org/10.1016/j.jacc.2016.05.011</mixed-citation></ref><ref id="hanspub.40296-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018 [J]. 中华心血管病杂志, 2018, 46(10): 760-789.</mixed-citation></ref><ref id="hanspub.40296-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Cesselli, D., Jakoniuk, I., Barlucchi, L., et al. (2001) Oxidative Stress-Mediated Cardiac Cell Death Is a Major Determinant of Ventricular Dysfunction and Failure in Dog Dilated Cardiomyopathy. Circulation Research, 89, 279-286.  
&lt;br&gt;https://doi.org/10.1161/hh1501.094115</mixed-citation></ref><ref id="hanspub.40296-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Berry, C.E. and Hare, J.M. (2004) Xanthine Oxidoreductase and Cardiovascular Disease: Molecular Mechanisms and Pathophysiologic Implications. The Journal of Physiology, 555, 589-606. &lt;br&gt;https://doi.org/10.1113/jphysiol.2003.055913</mixed-citation></ref><ref id="hanspub.40296-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Anker, S., Doehner, W., Rauchaus, M., et al. (2003) Uric Acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging. Circulation, 107, 1991-1997.  
&lt;br&gt;https://doi.org/10.1161/01.CIR.0000065637.10517.A0</mixed-citation></ref><ref id="hanspub.40296-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Kosmala, W., Holland, D.J., Rojek, A., et al. (2013) Effect of If-Channel Inhibition on Hemodynamic Status and Exercise Tolerance in Heart Failure with Preserved Ejection Fraction: A Randomized Trial. Journal of the American College of Cardiology, 62, 1330-1338. &lt;br&gt;https://doi.org/10.1016/j.jacc.2013.06.043</mixed-citation></ref></ref-list></back></article>